Precision oncology
See it. Treat it.
Using targeted radiation to combine imaging and therapy, Telix’s technology has the potential to change the way clinicians are able to find and treat cancer and rare diseases, to better inform treatment decisions and deliver truly personalised therapy for patients.
Molecularly targeted radiation (MTR)
Many existing cancer therapies are non-selective, impacting healthy tissue and vital organs at the same time as treating disease.
Existing external beam radiation therapy (EBRT) approaches are effective but typically only deliver localised treatment and also cause damage to surrounding tissue. Localised therapeutic approaches rely on the treating physician making assumptions about the extent of disease but missing even small amounts of surviving cells means the cancer or disease can recur over time.
MTR delivers targeted radiation to cancer cells with precision, regardless of where the cancer is in the body.
How does MTR work?
Targeted radiation drug
A radioactive isotope (“payload”) is attached to a targeting agent such as a small molecule or antibody, which has an affinity for unique biomarkers found on the surface of cancerous or diseased cells.
Depending on the payload, either imaging or therapy can be delivered.
Intravenous injection
The targeted radiation drug is administered into the bloodstream and circulates throughout the body.
Targeted delivery
Targeted radiation seeks out cancerous or diseased cells wherever they are, including small metastases (where the cancer has spread) and binds selectively to its target.
This is different from traditional radiation therapy, which is typically only delivered to a local tumour site.
See it. Treat it.
Some radioisotopes have physical properties that may be used to image cancer or rare diseases, for diagnosis and staging purposes.
Higher dose radiation with alpha- and beta-emitting radioisotopes can be used as therapies to destroy cancerous or diseased cells.